The Vitamin D Deficiency Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Vitamin D Deficiency Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vitamin D Deficiency Disorders. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vitamin D Deficiency Disorders and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Vitamin D Deficiency Disorders by nine companies/universities/institutes. The top development phase for Vitamin D Deficiency Disorders is preclinical with five drugs in that stage. The Vitamin D Deficiency Disorders pipeline has six drugs in development by companies and two by universities/ institutes. Some of the companies in the Vitamin D Deficiency Disorders pipeline products market are: Panorama Research Institute, Changchun GeneScience Pharmaceutical and Ultragenyx Pharmaceutical.

The key targets in the Vitamin D Deficiency Disorders pipeline products market include Fibroblast Growth Factor 23 (Phosphatonin or Tumor Derived Hypophosphatemia Inducing Factor or FGF23), Fibroblast Growth Factor Receptor (FGFR or EC 2.7.10.1), and Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9).

The key mechanisms of action in the Vitamin D Deficiency Disorders pipeline product include Fibroblast Growth Factor 23 (Phosphatonin or Tumor Derived Hypophosphatemia Inducing Factor or FGF23) Inhibitor with four drugs in Phase III. The Vitamin D Deficiency Disorders pipeline products include three routes of administration with the top ROA being Subcutaneous and five key molecule types in the Vitamin D Deficiency Disorders pipeline products market including Monoclonal Antibody, and Fusion Protein.

Vitamin D Deficiency Disorders overview

Vitamin D deficiency, or hypovitaminosis D, is due to lack or deficiency of fat-soluble vitamin D. Vitamin D plays an important role in calcium homeostasis and bone metabolism. It is most commonly seen in people who are not exposed to sunlight and have insufficient vitamin D in their diet. Some medications, including laxatives, steroids (prednisone), cholesterol-lowering drugs (cholestyramine and cholestipol), and anti-epileptics (phenobarbital and phenytoin), can also cause hypovitaminosis D. It can lead to osteomalacia in adults and rickets in children. It can cause muscle aches, joint deformities, weakness, and bone pain. It can be diagnosed with a vitamin D blood test. Fatty fish such as salmon, tuna, and mackerel; beef liver; cheese; mushrooms; and egg yolks are good sources of vitamin D. Vitamin D3 (cholecalciferol) supplementation has been shown to be more efficacious in achieving optimal 25-hydroxyvitamin D levels compared with vitamin D2 (ergocalciferol).

For a complete picture of Vitamin D Deficiency Disorders’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.